Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial
Early DHA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial
1 other identifier
interventional
152
1 country
1
Brief Summary
Growth-restricted very preterm infants (VPT) are born without adequate fat mass (FM) deposits and low docosahexaenoic acid (DHA) concentrations. They often experience further declines in DHA concentrations during the initial three weeks post-birth while advancing enteral feeds and receiving lipid supplementation predominantly through parenteral nutrition. These suboptimal enteral and parenteral nutrition practices significantly heighten the risk of faltering postnatal growth. One promising approach to mitigate these issues is enteral DHA supplementation. However, it remains unclear whether the early administration of DHA through enteral supplementation could lead to a more substantial increase in head growth without affecting FM accretion in growth-restricted VPT infants. To address this question, we propose a masked randomized clinical trial involving 152 VPT infants.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started May 2024
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 5, 2024
CompletedFirst Posted
Study publicly available on registry
January 16, 2024
CompletedStudy Start
First participant enrolled
May 20, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2026
ExpectedMay 30, 2025
May 1, 2025
1.9 years
January 5, 2024
May 26, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Head circumference at 36 weeks postmenstrual age or discharge
Declines in head circumference z scores from birth to 36 weeks postmenstrual age
Birth to 36 weeks postmenstrual age or discharge
Secondary Outcomes (2)
Fat mass(FM)-for-age Z-score
Birth to 36 weeks postmenstrual age
Changes in serum metabolic profile at 36 weeks postmenstrual age
36 weeks postmenstrual age or discharge
Other Outcomes (1)
Cognitive outcomes
2 years of age
Study Arms (2)
Intervention
ACTIVE COMPARATORA DHA/ARA supplement will be added to expressed human milk or donor human milk administered during the first 3 weeks after birth.
Control
NO INTERVENTIONNo DHA/ARA supplement will be added to expressed human milk or donor human milk administered during the first 3 weeks after birth.
Interventions
Eligibility Criteria
You may qualify if:
- Gestational ages between 22 0/7 - 32 6/7 weeks gestation
- \< 25th centile birthweight
You may not qualify if:
- Major congenital/chromosomal anomalies
- Terminal illness in which decisions to withhold or limit support have been made
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Alabama at Birminghamlead
- Mead Johnson Nutritioncollaborator
Study Sites (1)
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 5, 2024
First Posted
January 16, 2024
Study Start
May 20, 2024
Primary Completion
May 1, 2026
Study Completion (Estimated)
December 1, 2026
Last Updated
May 30, 2025
Record last verified: 2025-05